Technology ID
              TAB-778
          Peptides for Treatment of Tumor Necrosis Factor alpha Mediated Inflammatory Disease
E-Numbers
          E-208-2003-0
              Lead IC
          NHLBI
              Co-Inventors
          Levine, Stewart
              ICs
          NHLBI
              Applications
          Therapeutics
          Research Materials
          Diagnostics
              Therapeutic Areas
          Immunology
              Development Status
              - Early-stage
- In vitro data available
Tumor Necrosis Factor alpha (TNF-alpha) is a multifunctional cytokine that mediates inflammation, immune regulation, and cellular proliferation. This cytokine is converted to its active form by TNF-alpha converting enzyme (TACE). Pathological increases in TNF-alpha activity have been associated with a wide variety of inflammatory diseases, including inflammatory bowel disease, rheumatoid arthritis, and cancer. Inhibiting the conversion of TNF-alpha to its active form by inhibiting TACE represents a potential treatment for these diseases.
The current technology provides peptides, derived from an N-terminal fragment of the TACE protein, that inhibit TACE activity. Also described are methods of using these peptides to lower levels of active TNF-alpha. These peptides could be used as a treatment for TNF-alpha-mediated inflammatory diseases.
      
  The current technology provides peptides, derived from an N-terminal fragment of the TACE protein, that inhibit TACE activity. Also described are methods of using these peptides to lower levels of active TNF-alpha. These peptides could be used as a treatment for TNF-alpha-mediated inflammatory diseases.
Commercial Applications
              Treatment of TNF-alpha mediated inflammatory diseases.
      Competitive Advantages
              Inhibition of TACE activity represents a novel mechanism to treat inflammatory disease.
          Licensing Contact: